. Author manuscript; available in PMC: 2014 Jan 1.

Published in final edited form as: Cancer Causes Control. 2012 Oct 19;24(1):47–54. doi: 10.1007/s10552-012-0088-6

Table 4.

Interaction of CYP2C9 genotype and aspirin treatment or smoking status on risk of any adenoma recurrence

Subjects	Genotype	RR (95% CI)^b			P_int^c
		Aspirin Treatment Group
		Placebo	81 mg/day	325 mg/day
All races	Wild-type	1.0 (referent) [86/210]	0.79 (0.61–1.02) [68/214]	0.95 (0.74–1.21) [78/202]	0.85
All races	Variant^a	1.0 (referent)^d [49/93]	0.81 (0.60–1.08) [45/99]	0.87 (0.65–1.16) [50/106]
Non-Hispanic Whites	Wild-type	1.0 (referent) [71/170]	0.81 (0.61–1.07) [58/178]	0.94 (0.72–1.22) [67/173]	0.97
Non-Hispanic Whites	Variant^a	1.0 (referent)^e [44/85]	0.83 (0.61–1.12) [44/96]	0.91 (0.69–1.22) [47/96]

		Smoking Status
		Never	Former	Current
All races	Wild-type	1.0 (referent) [82/274]	1.26 (0.99–1.58) [105/258]	1.60 (1.19–2.15) [41/91]	0.04
All races	Variant^a	1.0 (referent)^f [62/122]	0.80 (0.62–1.03) [61/137]	1.03 (0.72–1.50) [21/39]
Non-Hispanic Whites	Wild-type	1.0 (referent) [72/233]	1.21 (0.95–1.56) [92/218]	1.47 (1.05–2.08) [30/67]	0.04
Non-Hispanic Whites	Variant^a	1.0 (referent)^g [62/118]	0.76 (0.58–0.99) [55/124]	0.98 (0.67–1.43) [18/35]

Combined genotype analysis where variant = one or more variant (minor) alleles at either CYP2C9*2 (R144C, rs1799853) or CYP2C9*3 (I359L, rs1057910).

Relative risk (RR) adjusted for age and sex; 95% confidence interval (95% CI); [#/#] = [# subjects with adenoma/total # subjects]

P_int = P for interaction of genotype with aspirin treatment or smoking status.

RR (95% CI) for variant vs. wild-type is 1.31 (1.00–1.72) among placebo subjects.

RR (95% CI) for variant vs. wild-type is 1.28 (0.96–1.71) among placebo subjects.

RR (95% CI) for variant vs. wild-type is 1.67 (1.30–2.16) among never smokers.

RR (95%CI) for variant vs. wild-type is 1.65 (1.27–2.14) among never smokers.